These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Novel treatments for men with lower urinary tract symptoms suggestive of benign prostate hyperplasia. Chung SD; Yu HJ J Formos Med Assoc; 2009 May; 108(5):349-52. PubMed ID: 19443288 [No Abstract] [Full Text] [Related]
29. Update on the relationship between sexual dysfunction and lower urinary tract symptoms/benign prostatic hyperplasia. Rosen RC Curr Opin Urol; 2006 Jan; 16(1):11-9. PubMed ID: 16385195 [TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice. Sánchez-Chapado M; Guil M; Alfaro V; Badiella L; Fernández-Hernando N Eur Urol; 2000 Apr; 37(4):421-7. PubMed ID: 10765072 [TBL] [Abstract][Full Text] [Related]
31. Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential complications. Fine SR; Ginsberg P J Am Osteopath Assoc; 2008 Jul; 108(7):333-7. PubMed ID: 18648026 [TBL] [Abstract][Full Text] [Related]
32. [Additional administration of dutasteride in patients with benign prostatic hyperplasia who did not respond sufficiently to α1-adrenoceptor antagonist : investigation of clinical factors affecting the therapeutic effect of dutasteride]. Masuda M; Murai T; Osada Y; Kawai M; Kasuga J; Yokomizo Y; Kuroda S; Nakamura M; Noguchi G Hinyokika Kiyo; 2014 Feb; 60(2):61-7. PubMed ID: 24755815 [TBL] [Abstract][Full Text] [Related]
33. Potential mechanisms of action of superselective alpha(1)-adrenoceptor antagonists. Price D Eur Urol; 2001; 40 Suppl 4():5-11. PubMed ID: 11786674 [TBL] [Abstract][Full Text] [Related]
34. Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia. Tarter TH; Vaughan ED Curr Pharm Des; 2006; 12(7):775-83. PubMed ID: 16515494 [TBL] [Abstract][Full Text] [Related]
35. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. Roehrborn CG BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681 [TBL] [Abstract][Full Text] [Related]
36. alpha-Adrenoceptor antagonists in the treatment of benign prostate hyperplasia. Thiyagarajan M Pharmacology; 2002 Jul; 65(3):119-28. PubMed ID: 12037374 [TBL] [Abstract][Full Text] [Related]
37. The role of combination medical therapy in benign prostatic hyperplasia. Greco KA; McVary KT Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123 [TBL] [Abstract][Full Text] [Related]
38. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard? Silva J; Silva CM; Cruz F Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531 [TBL] [Abstract][Full Text] [Related]
39. Medical management of lower urinary tract symptoms in men: current treatment and future approaches. Patel AK; Chapple CR Nat Clin Pract Urol; 2008 Apr; 5(4):211-9. PubMed ID: 18301417 [TBL] [Abstract][Full Text] [Related]
40. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. Emberton M; Elhilali M; Matzkin H; Harving N; van Moorselaar J; Hartung R; Alcaraz A; Vallancien G; Urology; 2005 Aug; 66(2):316-22. PubMed ID: 16098361 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]